On December 16, Aurigene Oncology Limited, a wholly owned subsidiary of Dr Reddy’s Laboratories, announced that it will discontinue clinical development of AUR-101, an oral medication for moderate to severe psoriasis, in the United States.
The chemical was in phase 2 of a clinical trial. Dr Reddy’s made the decision to halt the experiment in an exchange filing after Aurigene disclosed the findings of the Phase 2 trials of AUR 101.
“The primary endpoint of PASI-75 at 12 weeks at the 200 mg BID dose and the 400 mg QD dose were not met. There were no safety issues identified in the study. Aurigene will be closing the clinical development of AUR101 in psoriasis,” Aurigene Oncology said.
The level of efficacy increase with AUR101 (vs placebo) in psoriasis was less than expected, according to Murali Ramachandra, Chief Executive Officer of Aurigene.
Dr Reddy’s Lab shares fell 2.53 percent in afternoon trade on Friday on the National Stock Exchange to Rs 4,356.05, compared to Rs 4,468 at the previous day’s close.
According to the company, AUR-101 has been determined to be safe in preclinical toxicity tests, at many folds of efficacious human exposures, and has also demonstrated satisfactory pharmacodynamic modulation in previous clinical trials.
Aurigene stated in February 2020 that the first patient had been dosed with AUR101 in a Phase 2 research in individuals with moderate to severe psoriasis.
